-
FDA Approves Stiolto Respimat sNDA to Add Data on COPD Exacerbation Reduction
Boehringer Ingelheim announced the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & olodaterol...
2018-10-12 14:50 -
Rigel Receives EMA Validation for Fostamatinib
"The EMA's validation of our MAA is an important milestone in the execution of our global commercial strategy for fostamatinib for the t...
2018-10-12 14:44 -
Carrick bags ex-Onyx cancer drug, plans pivotal trials
Onyx paid BTG $13 million up front to license the drug in 2008 and handed over a further $7 million when it secured clearance to run a p...
2018-10-12 14:42 -
Australian Competition and Consumer Commission clears Arrow and Apotex merger: S
Strides Pharma Science has said that the Australian Competition and Consumer Commission (ACCC) has deci-ded not to oppose the merger of generic pharma...
2018-10-10 14:12 -
Aurobindo gets South African nod for HIV drug
Prior to SAHPRA’s approval, Aurobindo has received tentative approval for the drug from US Food and Drug Administration and launched in Sub-Saharan A...
2018-10-10 14:10 -
Lupin to train over 1,000 graduates for pharma industry
Mumbai-based Lupin expects to train more than 1,000 under graduates into pharma professionals by the year 2020 under its ‘Learn and Earn Initiative’...
2018-10-10 13:46 -
Sun Pharma and SPARC announce US FDA nod for glaucoma drug
Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) have announced USFDA approval for the New Drug Application (N...
2018-10-10 13:45 -
Govt. allows oxytocin sale by private chemists
The contentious drug oxytocin will now be allowed to be sold by private retail chemists, the Union Health Ministry has said. The alteration to its ear...
2018-09-05 14:27 -
Call to strengthen academia-industry partnership in pharma sector
The role of academia in strengthening the Indian pharma industry and boosting research was debated at Synergy 2018, a NIPER-pharma industry workshop h...
2018-09-05 14:26 -
Jubilant Life Sciences plans Rs. 550-crore capex in 2018-19
Jubilant Life Sciences has earmarked Rs. 550-crore for capital expenditure (capex) in the current financial year, while also planning to invest Rs. 30...
2018-08-31 14:35
Hot News
- “全球展会数据”功能上线公告 A... Dec 11, 2025
- 关于加强防范钓鱼邮件的通知 Not... Dec 11, 2025
- Global Chemical Giants Light t... Dec 05, 2025
- Dow’s “Double Salvo”: Behin... Dec 09, 2025
- Behind Arkema’s ￥430 Million... Dec 01, 2025
Related Products
Related Producers
